3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
35
Lung Neoplasms
9
Neoplasms
6
Neoplasm Metastasis
5
Carcinoma
5
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thoracic Neoplasms
1
Stage IB-IIIA Non-small Cell Lung Carcinoma
1
Skin Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Noonan Syndrome
1
Non Small Cell Lung Cancer Metastatic
1
Neoplasms, Squamous Cell
1
Neoplasms by Site
1
NSCLC
1
Multiple Myeloma
1
Lymphoma
1
Lung Diseases
1
Locally Advanced or Metastatic EGFR T790M+ NSCLC
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Hematologic Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Interventions
osimertinib
1
Radiotherapy
1
Nivolumab
1
Ipilimumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Non Small Cell Lung Cancer Metastatic
×
osimertinib
×
Clear all
NCT03133546
2026-02-06
BOOSTER
ETOP IBCSG Partners Foundation
Phase 2
Completed
155 enrolled
23 charts